Novo Nordisk Launches Wegovy in China With Prices Below US
- Major move toward unlocking the fast-growing mainland market
- Chinese buyers will have to pay largely out of pocket for drug
Wegovy production at the Novo Nordisk facilities in Hillerod, Denmark.
Photographer: Carsten Snejbjerg/BloombergThis article is for subscribers only.
Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key step in unlocking a big, fast-growing market for its blockbuster franchise.
The first prescription was issued on Monday to a 40-year-old man at Shanghai’s prestigious public Zhongshan Hospital, according to Chinese media outlet The Paper.